Login Register Cart 0
Generic placeholder image

Drug Metabolism and Bioanalysis Letters

Editor-in-Chief

ISSN (Print): 2949-6810
ISSN (Online): 2949-6829

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Determination of Olmesartan in Bulk and Pharmaceutical Dosage Forms through the Development and Validation of Stability-indicating RP-HPLC Method

Author(s): Akshita A. Agrawal, Jagdish K. Sahu*, Shilpa Dawre and Abhishek Kanugo

Volume 16, Issue 1, 2023

Published on: 20 March, 2023

Page: [65 - 72] Pages: 8

DOI: 10.2174/2949681016666230224153822

Price: $65

Abstract

Background: Angiotensin II type 1 (AT 1) receptor antagonist (angiotensin receptor blocker (ARB) called Olmesartan medoxomil (OLM) prevents angiotensin II from acting on the renin-angiotensin-aldosterone pathway, which is a crucial factor in the development of hypertension. OLM is reported to rapidly hydrolyze into its active metabolite, Olmesartan, in plasma after oral treatment.

Objective: The objective of the ongoing study was to develop an easy-to-use, precise, and reliable RP-HPLC method for the determination of Olmesartan in bulk as well as pharmaceutical dosage forms.

Methods: The stability indicating HPLC method for assay includes the use of Kromasil 100-5-C8 (100 mm × 4.6 mm) column, UV detector 265 nm, and mobile phase composition was a mixture of Acetonitrile: water (70:30) and flow rate of 1.0 mL/min. ICH guidelines were followed in the method's validation. To assess the method's specificity and stability in showing characteristics, stress degradation studies were carried out. The working standard solution of Olmesartan was exposed to 0.1 N HCl at room temperature, 0.1 N NaOH at room temperature, 30 percent hydrogen peroxide by volume, and UV radiation in order to conduct a degradation study.

Results: The retention periods of the drug were found to be 1.36 and 1.47 min for standard and sample solutions, respectively. The degradation behaviour of drug under different conditions was studied. The drug was found susceptible to acidic, alkaline and oxidative conditions while it was found stable in photolytic condition. The developed stability-indicating RP-HPLC method for assay was validated as per ICH Q2 guidelines and the validation parameters such as accuracy, precision and specificity were obtained within the accepted criteria.

Conclusion: It may be concluded that this method is stability-indicating and specific and can successfully be applied to analyze tablet dosage form containing Olmesartan.

« Previous
Graphical Abstract

[1]
Brunner, H.R. The new oral angiotensin II antagonist olmesartan medoxomil: A concise overview. J. Hum. Hypertens., 2002, 16(S2), S13-S16.
[http://dx.doi.org/10.1038/sj.jhh.1001391] [PMID: 11967728]
[2]
Laeis, P.; Püchler, K.; Kirch, W. The pharmacokinetic and metabolic profile of Olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens., 2001, 19(1), S21-S32.
[http://dx.doi.org/10.1097/00004872-200106001-00004] [PMID: 11451211]
[3]
Brunner, H.R. Olmesartan medoxomil: Current status of its use in monotherapy. Vasc. Health Risk Manag., 2006, 2(4), 327-340.
[http://dx.doi.org/10.2147/vhrm.2006.2.4.327] [PMID: 17323586]
[4]
Li, K.Y.; Liang, J.P.; Hu, B.Q.; Qiu, Y.; Luo, C.H.; Jiang, Y.; Lin, X.P.; Yang, N. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Clin. Ther., 2010, 32(9), 1674-1680.
[http://dx.doi.org/10.1016/j.clinthera.2010.08.004] [PMID: 20974325]
[5]
Raghunathan, K.; Reddy, J.M.; Manasa, R. Stability indicating RP-HPLC method development and validation of Olmesartan medoxomil. Asian J. Pharm. Sci, 2011, 1, 79-86.
[6]
Chaitanya Prasad, M.K.; Vidyasagar, G.; Sambasiva Rao, K.R.S.; Ramanjeneyulu, S. Development of RP-HPLC method for estimation of Olmesartan medoxomil in tablet dosage forms. Pharma Chem., 2011, 3, 208-212.
[7]
Hamrapurkar, P.D.; Gadapayale, K.K. Optimization and validation of Rp – HPLC stability indicating method for determination of olmesartan medoxomil and its degraded product. Int. J. Appl. Sci. Eng., 2013, 11, 137-147.
[8]
Tambe, S.R.; Shinde, R.H.; Gupta, L.R.; Pareek, V.; Bhalerao, S.B. Development of LLE and SPE procedures and its applications for determination of olmesartan in human plasma using RP-HPLC and HPTLC. J. Liq. Chromatogr. Relat. Technol., 2012, 35, 423-430.
[http://dx.doi.org/10.1080/10826070903571358]
[9]
Gandurib, R.B.; Lankaa, R.A.; Pamidia, S.; Peddareddigarib, J.R.; Mohammed, M. New RP-HPLC method for the determination of Olmesartan medoxomil in tablet dosage form. Eur. J. Anal. Chem., 2010, 5, 145-151.
[10]
Sharma, R.; Pancholi, S. RP-HPLC-DAD method for determination of Olmesartan medoxomil in bulk and tablets exposed to forced conditions. Acta Pharm., 2010, 60(1), 13-24.
[http://dx.doi.org/10.2478/v10007-010-0010-2] [PMID: 20228038]
[11]
Pai, N.R.; Sawant, S.S. Development and validation of new RP-HPLC method for determining impurity profiling in Olmesartan medoxomil drug as well as in tablet dosage form. Pharma Chem., 2013, 5, 274-281.
[12]
Raj, S.; Kumari, K.S.; Rao, A.N.; Reddy, I.U.; Raju, M.N. Development of a stability-indicating UPLC method for determination of Olmesartan medoxomil and its degradation products in active pharmaceutical ingredient and dosage forms. J. Liq. Chromatogr. Relat. Technol., 2012, 35(8), 1011-1026.
[http://dx.doi.org/10.1080/10826076.2011.615091]
[13]
Vaidya, V.V.; Roy, S.M.N.; Yetal, S.M.; Joshi, S.S.; Parekh, S.A. LC–MS–MS determination of olmesartan in human plasma. Chromatographia, 2008, 67(1-2), 147-150.
[http://dx.doi.org/10.1365/s10337-007-0453-x]
[14]
Liu, D.; Hu, P.; Matsushima, N.; Li, X.; Li, L.; Jiang, J. Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 856(1-2), 190-197.
[http://dx.doi.org/10.1016/j.jchromb.2007.05.049] [PMID: 17602900]
[15]
Görög, S. The paradigm shifting role of chromatographic methods in pharmaceutical analysis. J. Pharm. Biomed. Anal., 2012, 69, 2-8.
[http://dx.doi.org/10.1016/j.jpba.2012.01.031] [PMID: 22341481]
[16]
Orlandini, S.; Pinzauti, S.; Furlanetto, S. Application of quality by design to the development of analytical separation methods. Anal. Bioanal. Chem., 2013, 405(2-3), 443-450.
[http://dx.doi.org/10.1007/s00216-012-6302-2] [PMID: 22941176]
[17]
Verma, P.; Kamboj, V.; Sethi, B. Development and validation of an RP-HPLC method for estimation of Olmesartan medoxomil in tablet formulations and stability studies. J. Pharm. Res., 2010, 3, 1015-1018.
[18]
Jyothirmai, B.; Tnvss, S.; Santosh, T.; Syama, S. B. Development and validation of an RP-HPLC method for the determinaton of olmesartan in human plasma. Int. J. Res. Pharm. Chem., 2014, 4(2), 457-466.
[19]
Bharti, T.; Mishra, R.; Rajput, C.S.; Singhal, R. Analytical method development and validation of assay for Olmesartan medoxomil in formulated product by reverse phase ultra-performance liquid chromatography. Euro. J. Biomed. Pharm. Sci., 2016, 3(2), 215-222.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy